![](https://medcitynews.com/wp-content/uploads/sites/7/2022/08/nci-vol-2288-150.jpg)
Eisai Strikes Cancer Alliance to Line Up Potential Challenger to AstraZeneca Drug
Eisai gains an option to license a Bliss Biopharmaceutical drug that targets HER2, a cancer protein that has become a hot target for addressing several types of solid tumors. BlissBio could receive up to $2 billion in milestones and other payments.